Cell and Gene Manufacturing and Logistics

  1. CGT Modality, Hybrid Models, And What To Keep In-House 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech examining how modality changes the CGT manufacturing decision framework, with autologous programs requiring patient-specific coordination and allogeneic and in vivo approaches opening different paths for scale and inventory.

  2. CGT Biotech/CDMO Transparency & Core Capabilities 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech sharing what CGT developers should look for in a CDMO partnership, including transparency, data visibility, and capability rather than just capacity. The panelists reinforce that CGT companies should retain deep product knowledge, CMC strategy, quality oversight, and regulatory understanding in-house. 

  3. How to Match CGT Manufacturing Models to Pipeline Needs 7/9/2026

    This opening segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech discussing how early manufacturing decisions shape scalability and commercialization.

  4. Revisiting CGT Manufacturing Strategy and De-Risking Tech Transfer 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech focusing on when CGT developers should start stress-testing manufacturing strategy, emphasizing that planning should begin as early as phase one and be revisited as clinical data, demand forecasts, and process knowledge evolve. 

  5. Supply Chain Orchestration, Priorities for Smaller CGT Biotechs 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech focuses on supply chain orchestration as a control-tower challenge, with the biggest vulnerabilities showing up in patient scheduling, data fragmentation, and QC/release bottlenecks.

  6. Future CGT Manufacturing Trends, AI Reality Checks, and Phase 1 Strategy 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech discussing the innovations most likely to impact CGT commercialization, such as closed automated platforms that generate continuous process data, AI-driven faster analytics and predictive release, and digital orchestration that connects clinical scheduling, manufacturing, logistics, and quality in real time.

  7. FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy 7/9/2026

    Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.

  8. Negative Stain TEM For Viral Particle Characterization 7/8/2026

    Standardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.

  9. Maximizing Efficiency In Lentiviral Vector Manufacturing 7/8/2026

    Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.

  10. Automatic Filling And Capping Machine In Aseptic Conditions 7/7/2026

    AseptiFill is the Aseptic Filling and Capping Machine specifically designed for Pharma & Biotech companies, focused on small batch production of injectable products for pre-clinical and clinical trial studies. Suitable for Ready-To-Use (RTU) vials ISO 8362-1 and RayDyLyo® push-fit caps.